Patient-reported outcomes (PROs) <65 or ≥ 65 years old (yo) from CARES-310 camrelizumab plus rivoceranib vs sorafenib as first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC)

被引：1

作者：

Chan, Stephen Lam

Kaseb, Ahmed Omar

Shi, Wei

Alexander, Laura

Meng, Xianzhang

Park, Cheolhee

Ryan, Kristin

Vogel, Arndt

机构：

[1] Chinese Univ Hong Kong, Hong Kong Canc Inst, Dept Clin Oncol, State Key Lab Translat Oncol, Hong Kong, Peoples R China

[2] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX USA

[3] Jiangsu Hengrui Pharmaceut, Shanghai, Peoples R China

[4] Elevar Therapeut, Ft Lee, NJ USA

[5] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期

关键词：

D O I：

10.1200/JCO.2024.42.3_suppl.456

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：456 / 456

页数：1

共 33 条

[21] Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): CheckMate 9DW Asian subgroup analysis
Yau, T.
Galle, P. R.
Decaens, T.
Sangro, B.
Qin, S.
Park, J-W.
Ikeda, M.
Tai, D. W. M.
Chiu, C-F.
Chon, H. J.
Kang, Y-K.
Hiraoka, A.
Huang, Y-H.
Lee, T-Y.
Numata, K.
Yamashita, T.
Ogata, T.
Hreiki, J.
Lu, Y.
Kudo, M.
ANNALS OF ONCOLOGY, 2024, 35 : S1450 - S1451
[22] Comparing first-line (1L) atezolizumab plus bevacizumab (A plus B) to lenvatinib (L) or sorafenib (S) in patients with unresectable hepatocellular carcinoma (uHCC): Findings from the National Veteran Health Administration (VHA) database.
Kaplan, David Edward
Tan, Amie
Xiang, Cheryl
Mu, Fan
Ogale, Sarika
Hernandez, Sairy
Li, Jiayang
Lin, Yilu
Shi, Lizheng
Singal, Amit G.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 446 - 446
[23] Patient-reported outcomes (PROs) from JAVELIN Bladder 100: Avelumab first-line (1L) maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC)
Powles, T. B.
Kopyltsov, E.
Su, P-J.
Parnis, F. X.
Park, S. H.
Yamamoto, Y.
Fong, P. C.
Tournigand, C.
Duran, M. A. Climent
Bamias, A.
Caserta, C.
Chang, J.
Yan, E.
di Pietro, A.
Wang, J.
Grivas, P.
ANNALS OF ONCOLOGY, 2020, 31 : S578 - S579
[24] IMbrave150: Updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC).
Finn, Richard S.
Qin, Shukui
Ikeda, Masafumi
Galle, Peter R.
Ducreux, Michel
Kim, Tae-You
Kudo, Masatoshi
Lim, Ho Yeong
Breder, Valeriy
Merle, Philippe
Kaseb, Ahmed
Li, Daneng
Feng, Yin-Hsun
Verret, Wendy
Nicholas, Alan
Li, Lindong
Ma, Ning
Zhu, Andrew X.
Cheng, Ann-Lii
CANCER RESEARCH, 2021, 81 (13)
[25] IMbrave150: updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC)
Finn, Richard S.
Qin, Shukui
Ikeda, Masafumi
Galle, Peter R.
Ducreux, Michel
Mertens, Joachim
Kim, Tae-You
Kudo, Masatoshi
Lim, Ho Yeong
Breder, Valeriy
Merle, Philippe
Kaseb, Ahmed
Li, Daneng
Feng, Yin-Hsun
Verret, Wendy
Nicholas, Alan
Li, Lindong
Ma, Ning
Zhu, Andrew X.
Cheng, Ann-Lii
SWISS MEDICAL WEEKLY, 2021, 151 : 25 - 26
[26] First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm plus ) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs).
Hirsh, Vera
Yang, James Chih-Hsin
Tan, Eng-Huat
O'Byrne, Ken
Zhang, Li
Boyer, Michael J.
Mok, Tony
Lee, Ki Hyeong
Lu, Shun
Shi, Yuankai
Kim, Sang-We
Laskin, Janessa J.
Kim, Dong-Wan
Arvis, Catherine Dubos
Kolbeck, Karl
Schuler, Martin H.
Massey, Dan
Maerten, Angela
Paz-Ares, Luis
Park, Keunchil
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[27] Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+gastroesophageal adenocarcinoma
Lordick, Florian
Al-Batran, Salah-Eddin
Ganguli, Arijit
Morlock, Robert
Sahin, Ugur
Tuereci, Oezlem
GASTRIC CANCER, 2021, 24 (03) : 721 - 730
[28] Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma
Florian Lordick
Salah-Eddin Al-Batran
Arijit Ganguli
Robert Morlock
Ugur Sahin
Özlem Türeci
Gastric Cancer, 2021, 24 : 721 - 730
[29] Patient-reported outcomes (PROs) among men receiving talazoparib (TALA) plus enzalutamide (ENZA) vs placebo (PBO) plus ENZA as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC): Results from a phase 3 study (TALAPRO-2)
Agarwal, Neeraj
Azad, Arun
Matsubara, Nobuaki
Saad, Fred
De Giorgi, Ugo
Joung, Jae Young
Fong, Peter C. C.
Jones, Robert J.
Zschaebitz, Stefanie
Oldenburg, Jan
Shore, Neal D.
Dunshee, Curtis
Carles, Joan
Fay, Andre P.
Cislo, Paul
Chang, Jane
Healy, Cynthia G.
Niyazov, Alexander
Fizazi, Karim
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[30] Nivolumab (Nivo) plus Ipilimumab (Ipi) vs Platinum-Doublet Chemotherapy (Chemo) as First-line (1L) Treatment (Tx) for Advanced Non-Small Cell Lung Cancer (NSCLC): Safety Analysis and Patient-Reported Outcomes (PROs) From CheckMate 227.
Reck, Martin
Hellmann, Matthew David
Paz-Ares, Luis G.
Ramalingam, Suresh S.
Brahmer, Julie R.
O'Byrne, Kenneth John
Bhagavatheeswaran, Prabhu
Nathan, Faith Ellen
Borghaei, Hossein
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 2 3 4 →

Patient-reported outcomes (PROs) &lt;65 or ≥ 65 years old (yo) from CARES-310 camrelizumab plus rivoceranib vs sorafenib as first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC)

Patient-reported outcomes (PROs) <65 or ≥ 65 years old (yo) from CARES-310 camrelizumab plus rivoceranib vs sorafenib as first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC)